Under the terms of the agreement, Vipergen will apply its in-living-cell DNA-encoded library (DEL) screening platform to discover novel small-molecule compounds that bind to a selected Theseus kinase target
Highlighted as game changer in drug development & delivery special feature on innovative technologies for improving drug solubility and bioavailability
The study was published recently in Genome Medicine, a leading international journal focused on translational, genomic-based medicine
Successful proposals will secure fully funded postdoctoral research positions
Career achievement for contributions in Physiologically based pharmacokinetic (PBPK) and biologically based does response (BBDR) modelling tools
Machine learning approach to systems biology combined with ligand discovery platform
These new chemical entities are covered by composition of matter patent applications. Financial terms of the deal were not disclosed
The Mechanisms of Inherited Kidney Disorders (MIKADO) group at the University of Zurich (UZH) and Insilico Medicine will be working together to identify, rank, and annotate novel drug targets to identify potential therapeutics for cystinosis
The phosphine ligand is available on the kilo scale for the first time, providing scientists with a powerful solution for cross-coupling chemistry
The products are based on a combination of mushrooms and cannabinoids that have achieved a strong therapeutic effect using low concentrations of THC. The treatment is expected to be launched in Israel, US and UK in H2 2022
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
